ImmunityBio, Inc. Common Stock

Day range

$7.75 – $8.28

Open

$8.23

Prev close

$8.22

Volume

8.6M

Market cap

$8.71B

Shares out

1.06B

P/E

—

P/S

52.55

P/B

-8.32

P/FCF

—

ROE

94.8%

ROA

-157.9%

Debt/Equity

-0.40

Div yield

0.00%

As of Oct 23, 2026

• Regulatory decisionOct 14, 2026

  On October 14, 2026, ImmunityBio, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) to include patients with BCG-unresponsive NMIBC with papillary-only tumors.

• Quarterly earningsAug 4, 2026

  On August 4, 2026, ImmunityBio, Inc. (the Company) issued a press release providing a business update and announcing its financial results for the three and six months ended June 30, 2026, and its financial position as of June 30, 2026.

• Regulatory decisionJul 30, 2026

  the Emirates Drug Establishment ("EDE") of the United Arab Emirates ("UAE") has granted marketing authorization for ANKTIVA® across two indications.

• Annual meeting resultsJun 10, 2026

  On June 9, 2026, ImmunityBio, Inc. held its 2026 Annual Meeting of Stockholders. The following nominees were re-elected by the holders of our Common Stock to serve as directors for a one year term expiring at the 2027 annual meeting of stockholders based on the following results of voting.

• Supply or distribution agreementMay 18, 2026

  On May 14, 2026, ImmunityBio, Inc., a Delaware corporation ('ImmunityBio' or the 'Company'), entered into an exclusive development and supply agreement (the 'Agreement') with Japan BCG Laboratory, a Japanese corporation ('JBL'). Pursuant to the Agreement, JBL will manufacture and exclusively supply Tokyo-172 strain of Bacillus Calmette-Guerin ('BCG') (the 'Product') to ImmunityBio for use in the United States and its territories (the 'Territory').

Days to cover

8.9

Short interest

124.09M

Avg volume

13.97M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer
  positiveZacks Investment Research· Oct 15, 2026
• INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
  negativeGlobeNewswire Inc.· May 26, 2026
• IBRX DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX
  negativeGlobeNewswire Inc.· May 25, 2026
• IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
  negativeGlobeNewswire Inc.· May 25, 2026
• IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX
  negativeGlobeNewswire Inc.· May 22, 2026